Evidence map›Paper›PMID 29187171›Full record

ArticleBMC pulmonary medicine2017

Antibiotic duration and changes in FEV

Julia C Espel, Hannah L Palac, Joanne F Cullina, Alexandria P Clarke, Susanna A McColley, Michelle H Prickett, Manu Jain

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Julia C EspelDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, 240 E. Huron Ave., McGaw Mezzanine, Chicago, IL, 60611, USA.
Hannah L PalacDepartment of Preventive Medicine, Northwestern University, Chicago, IL, USA.
Joanne F CullinaLurie Children's Hospital, Chicago, IL, USA.
Alexandria P ClarkeDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, 240 E. Huron Ave., McGaw Mezzanine, Chicago, IL, 60611, USA.
Susanna A McColleyLurie Children's Hospital, Chicago, IL, USA.
Michelle H PrickettDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, 240 E. Huron Ave., McGaw Mezzanine, Chicago, IL, 60611, USA.
Manu JainDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, 240 E. Huron Ave., McGaw Mezzanine, Chicago, IL, 60611, USA. m-jain@northwestern.edu.ORCID http://orcid.org/0000-0003-1534-5629
Northwestern University · USLurie Children's Hospital · US

Funding

Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8M
National Institutes of Health UL1TR001422NCATS NIH HHS UL1 TR001422
6 · The paper itself

Abstract

backgroundPulmonary exacerbations (PEx) are a major driver of morbidity and mortality in cystic fibrosis and reducing their frequency by extending the time between them is an important therapeutic goal. Although treatment decisions for exacerbations are often made based on dynamic changes in lung function, it is not clear if these changes truly impact future exacerbation risk. We analyzed adults with chronic Pseudomonas aeruginosa infection to determine whether changes in FEV

methodsMedical records and Cystic Fibrosis Foundation Patient Registry data were examined retrospectively to assess whether various patient-specific demographic factors and exacerbation-specific characteristics were associated with time until next exacerbation using the Andersen-Gill model in order to control for previous exacerbation frequency history.

resultsWe examined 59 patients with 221 CF pulmonary exacerbations over a 3-year study period. Mean age was 28.2 years and mean baseline FEV

conclusionsFEV1 drop and recovery associated with onset and treatment of a CF pulmonary exacerbation or duration of intravenous antibiotics were not predictive of time until next exacerbation. Our finding that older age may be associated with decreased hazard of exacerbation is likely due to a healthy survivor effect and should be controlled for in clinical trials of pulmonary exacerbations.

Indexed as

Pseudomonas aeruginosaAdultAge FactorsAnti-Bacterial AgentsChronic DiseaseCystic FibrosisDisease ProgressionFemaleForced Expiratory VolumeHumansMalePseudomonas InfectionsRegistriesRetrospective StudiesTime FactorsYoung AdultAnti-Bacterial AgentsAntibioticsBronchiectasisCystic fibrosisExacerbationOutcomes Pseudomonas aeruginosa

Identifiers

PMID29187171
PMCPMC5707785
OpenAlexW2768474139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.